FEB 2011

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: https://digital.eyeworld.org/i/307191

Contents of this Issue


Page 1 of 103

Drops end of year 18 Drops end of year 1 Drops end of year 10 ,23ORZHULQJFDQVWDUW ZLWKWKHYHU\ÀUVW GURSZLWK%$.IUHH 75$9$7$1= 6ROXWLRQ 0DQDJLQJ\RXU SDWLHQW·V,23 EHJLQVZLWK RQHGURS DQGFRQWLQXHV GURSDIWHUGURS DIWHUGURS Drops end of year 5 *Based upon patient age of 60 years, dosing prostaglandin analogue once daily in both eyes for 18 years. 2 References: 1. TRAVATAN Z® Solution [package insert]. Fort Worth, TX: Alcon; 2010. 2. Heron MP, Hoyert DL, Xu JQ, et al. Deaths: Preliminary Data for 2006. National vital statistics reports; vol 56 no 16. Hyattsville, MD: National Center for Health Statistics. 2008. travatanz.com ©2010 Alcon, Inc. 12/10 TRV10514JA INDICATIONS AND USAGE TRAVATAN Z® Solution is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. DOSING AND ADMINISTRATION One drop in the affected eye(s) once daily in the evening. IMPORTANT SAFETY INFORMATION: WARNINGS AND PRECAUTIONS Pigmentation: Pigmentation of the iris, periorbital tissue (eyelid) and eyelashes can occur. Iris pigmentation likely to be permanent. Eyelash changes: Gradual change to eyelashes including increased length, thickness and number of lashes. Usually reversible. ADVERSE REACTIONS Most common adverse reaction (30% to 50%) is conjunctival hyperemia. USE IN SPECIFIC POPULATIONS Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use. Before prescribing TRAVATAN Z ® Ophthalmic Solution, please read the full prescribing information.

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld - FEB 2011